Lucid Capital initiated coverage of Vistagen (VTGN) with a Buy rating and $19 price target The company is developing the first drug, fasedienol, to treat social anxiety disorder episodically, when needed, the analyst tells investors in a research note. The firm views social anxiety disorder episodically as an underserved condition.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Vistagen Therapeutics’ Earnings Call: Progress Amid Challenges
- VistaGen Therapeutics: Strong Cash Position and Promising Drug Pipeline Drive Buy Rating
- Vistagen Therapeutics Reports Progress in Clinical Trials
- VistaGen Reports Q1 2026 Financial Results and Update
- Vistagen reports Q1 EPS (47c), consensus (44c)